The Intensity Dependence of Auditory Evoked ERP Components Predicts Responsiveness to Reboxetine Treatment in Major Depression

Abstract

This result corroborates the hypothesis of the IDAP as a differential indicator of serotonergic versus noradrenergic antidepressant psychopharmacotherapy.

Review on EEG and ERP predictive biomarkers for major depressive disorder

“…For example, higher LDAEP slopes were found to be correlated with R [133]. In addition, lower LDAEP slopes at baseline were associated with treatment response to reboxetine [131]. Furthermore, higher values of LDAEP in R were observed compared to NR [132].…”

“…The ERP components, P300 intensities and latencies were found to be correlated with the treatment outcome for MDD patients [128][129][130][131][132]. The ERP type called the Loudness Dependence Auditory Evoked Potential (LDAEP) describes how one EPR component (N100/P200) changes with increasing loudness of the auditory stimulus.…”

Loudness dependence of auditory evoked potentials (LDAEP) correlates with the availability of dopamine transporters and serotonin transporters in healthy volunteers—a two isotopes SPECT study

“…However, these results could not be duplicated by other research groups (Daumann et al 2006;Guille et al 2008;Juckel et al 2007;O'Neill et al 2008a;Roser et al 2009). According to the review by O'Neill et al (2008a), the LDAEP shows more promise as a potential predictor of antidepressant treatment responses Lee et al 2005;Linka et al 2005;Mulert et al 2007;Pogarell et al 2007a), although the acute depletion studies in humans that provide little evidence of LDAEP is sensitive to the acute changes in 5-HT function (Debener et al 2002;Norra et al 2008;O'Neill et al 2008b).…”

Electrophysiological predictors of clinical response to antidepressants

“…Among 16 patients having a MDD, stronger pretreatment loudness dependency of N1 was associated with greater reduction in depression following 3-4 weeks of treatment with the SSRI citalopram (Linka et al, 2004). In contrast, in 14 patients tested before treatment with a noradrenaline reuptake inhibitor (NRI) reboxetine, smaller loudness dependency of N1 was associated with greater improvement in depression (Linka et al, 2005). In the first study in which depressed patients were randomly assigned to treatment with either the citalopram or reboxetine, Mulert et al (2007) measured LDAEP for current source distribution (latency window of 60-240 ms) localized using LORETA to primary auditory cortex.…”